Clinical Trial Update: Residual Disease Driven Strategy for CARCIK (CD19) in Adults/Pediatric BCP-ALL [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update exploring a residual disease-driven strategy for CARCIK (CD19) in adults and pediatric patients with B-cell precursor acute lympho…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia

Drugs mentioned

• CARCIK-CD19

Snippet

Sponsor: Fondazione Matilde Tettamanti Menotti De Marchi Onlus | Conditions: Acute Lymphoblastic Leukemia | Phase 2 | Status: UNKNOWN